These results suggested that AML patients with NEDD9 overexpression may benefit from HSCT, and NEDD9 expression might act as a potential biomarker guiding treatment selection between HSCT and chemotherapy in patients with AML after achieving CR by induction therapy. The gene discussed is NEDD9; the disease is acute myeloid leukemia.